Entera Bio

Entera Bio Current Liabilities

The Current Liabilities of Entera Bio (ENTX) as of Oct 8, 2026 is 2.20 M USD. In the previous year, Current Liabilities was 2.22 M USD — a change of -0.77% (lower).

Current Liabilities

2.20 MUSD

YoY

-0.77%

Last updated:

Current Liabilities of Entera Bio is 2025 2.20 M USD. Current Liabilities of Entera Bio was 2024 2.22 M USD. It decreases by -0.77% lower compared to the previous year.

The Entera Bio Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
1.56 M USD
Jan 1, 2019
5.65 M USD
Jan 1, 2020
3.20 M USD
Jan 1, 2021
5.99 M USD
Jan 1, 2022
2.66 M USD
Jan 1, 2023
2.10 M USD
Jan 1, 2024
2.22 M USD
Jan 1, 2025
2.20 M USD
The Entera Bio Current Liabilities history
YEARCurrent LiabilitiesYoY
2.20 MUSD-0.77%
2.22 MUSD+5.76%
2.10 MUSD-21.12%
2.66 MUSD-55.59%
5.99 MUSD+87.07%
3.20 MUSD-43.26%
5.65 MUSD+261.16%
1.56 MUSD-96.15%
40.58 MUSD+94.32%
20.88 MUSD-6.23%
22.27 MUSD—
Access this data via the Eulerpool API
Get Free API Key

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

Current Liabilities of Entera Bio is 2.20 M USD in 2025.

Current Liabilities of Entera Bio changed from 2.22 M USD to 2.20 M USD, representing a -0.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Entera Bio since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Entera Bio historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Entera Bio

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Entera Bio